SCHEMBL4159503

SCHEMBL4159503

O=C(O)Cc1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)NC4CCCNC4)cc3c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 1/20 0.43
TDP1 Q9NUW8 3/20 0.41
KDR P35968 1/20 0.41
BRAF P15056 1/20 0.38
BACE1 P56817 1/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36
IKBKB O14920 1/20 0.35
JAK2 O60674 1/20 0.35
ROCK2 O75116 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
ROCK1 Q13464 1/20 0.35
MAPT P10636 5/20 0.35
TP53 P04637 4/20 0.35
POLB P06746 4/20 0.35
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4166849 0.91 TDP1 (0.50) PARGTDP1BRAFBACE1PTGDR2
SCHEMBL4162615 0.90 TDP1 (0.52) PARGTDP1BRAFBACE1PTGDR2
SCHEMBL4162549 0.90 PARG (0.48) PARGTDP1KDRBRAFBACE1
SCHEMBL3242768 0.87 PARG (0.45) PARGTDP1KDRBRAFBACE1
SCHEMBL3254149 0.83 TDP1 (0.43) PARGTDP1KDRBRAFIKBKB
SCHEMBL4157648 0.82 TDP1 (0.50) PARGTDP1BRAFPTGDR2MAPT
SCHEMBL4153172 0.82 TDP1 (0.50) PARGTDP1BRAFPTGDR2MAPT
SCHEMBL3249352 0.82 TDP1 (0.42) PARGTDP1KDRBRAFIKBKB
SCHEMBL4168574 0.81 PARG (0.46) PARGTDP1KDRBRAFBACE1
SCHEMBL4153573 0.81 PARG (0.52) PARGTDP1BRAFMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 PARG 3507/4885TDP1 1098/4885KDR 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.